Ben Berkhout1, Olivier ter Brake. 1. Academic Medical Center of the University of Amsterdam, Center for Infection and Immunity Amsterdam (CINIMA), Department of Medical Microbiology, Laboratory of Experimental Virology, Amsterdam, The Netherlands. b.berkhout@amc.uva.nl
Abstract
BACKGROUND: RNA interference (RNAi) can be employed as a potent antiviral mechanism. OBJECTIVE: To discuss RNAi approaches to target pathogenic human viruses causing acute or chronic infections, in particular RNAi gene therapy against HIV-1. METHODS: A review of relevant literature. RESULTS/ CONCLUSIONS: The future of antiviral RNAi therapeutics is very promising. RNAi was discovered only a decade ago, and although we are still in the early days, the first clinical trials are already ongoing.
BACKGROUND: RNA interference (RNAi) can be employed as a potent antiviral mechanism. OBJECTIVE: To discuss RNAi approaches to target pathogenic human viruses causing acute or chronic infections, in particular RNAi gene therapy against HIV-1. METHODS: A review of relevant literature. RESULTS/ CONCLUSIONS: The future of antiviral RNAi therapeutics is very promising. RNAi was discovered only a decade ago, and although we are still in the early days, the first clinical trials are already ongoing.
Authors: Jiehua Zhou; C Preston Neff; Xiaoxuan Liu; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; Tawfik Aboellail; Yuanyu Huang; Quan Du; Zicai Liang; Ling Peng; Ramesh Akkina; John J Rossi Journal: Mol Ther Date: 2011-09-27 Impact factor: 11.454
Authors: Michael P Gantier; Stephen Tong; Mark A Behlke; Aaron T Irving; Martha Lappas; Ulrika W Nilsson; Eicke Latz; Nigel A J McMillan; Bryan R G Williams Journal: Mol Ther Date: 2010-02-02 Impact factor: 11.454